Dianthus Therapeutics (NASDAQ:DNTH) SVP Adam Veness Sells 3,833 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 3,833 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $110.70, for a total transaction of $424,313.10. Following the completion of the transaction, the senior vice president owned 3,833 shares of the company’s stock, valued at $424,313.10. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Dianthus Therapeutics Stock Down 3.0%

Shares of DNTH stock opened at $108.49 on Wednesday. Dianthus Therapeutics, Inc. has a 12-month low of $19.00 and a 12-month high of $114.55. The firm has a fifty day moving average of $95.71 and a 200-day moving average of $81.79. The company has a market capitalization of $5.93 billion, a price-to-earnings ratio of -26.14 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. On average, equities analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. First Horizon Corp acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $32,000. Global Retirement Partners LLC acquired a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $93,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at $40,000. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics during the second quarter worth $27,000. Finally, Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics during the third quarter worth $64,000. 47.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on DNTH shares. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. HC Wainwright upped their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright issued an optimistic estimate for Dianthus Therapeutics’ earnings, offering a potential bullish catalyst for DNTH. However, the report did not provide specific revised earnings targets. HC Wainwright Issues Optimistic Estimate for DNTH Earnings
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting period, with a days-to-cover ratio of zero. This indicates little evidence of active short-selling pressure or a potential short squeeze in DNTH.
• Negative Sentiment: Several insiders sold shares around $109 to $111. Senior Vice President Adam M. Veness sold 20,000 shares across transactions on August 7 and August 10 for approximately $2.21 million, reducing his position by roughly 80.8% overall. SEC insider trading filing
• Negative Sentiment: Director Simon Read sold 2,777 shares for about $304,000, cutting his holdings by 50%. Director Anne McGeorge sold 7,750 shares for approximately $845,000, reducing her position by about 86%. The timing and size of these sales could raise concerns because they occurred while the stock was trading near its 12-month high. SEC director trading filing

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.